Sustained gene knockdown by the aid of a well-known biodegradable polymer has shown that old materials can still be used to solve new problems.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer
Scientific Reports Open Access 14 May 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fire, A. et al. Nature 391, 806–811 (1997).
Whitehead, K. A., Langer, R. & Anderson, D. G. Nature Rev. Drug Discov. 8, 129–138 (2009).
Woodrow, K. A. et al. Nature Mater. 8, 526–533 (2009).
Kumar, P. et al. Cell 134, 577–586 (2008).
Palliser, D. et al. Nature 439, 89–94 (2006).
Gu, W. et al. Cancer Gene Ther. 13, 1023–1032 (2006).
Putney, S. D. & Burke, P. A. Nature Biotech. 16, 153–157 (1998).
Luo, D., Woodrow-Mumford, K., Belcheva, N. & Saltzman, W. M. Pharm. Res. 16, 1300–1308 (1999).
Cu, Y. & Saltzman, W. M. Mol. Pharm. 6, 173–181 (2009).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Campolongo, M., Luo, D. Old polymer learns new tracts. Nature Mater 8, 447–448 (2009). https://doi.org/10.1038/nmat2456
Issue Date:
DOI: https://doi.org/10.1038/nmat2456
This article is cited by
-
Biomaterials as Antigen Delivery Carrier for Cancer Immunotherapy
Macromolecular Research (2021)
-
PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer
Scientific Reports (2018)
-
VIP-loaded PLGA as an anti-asthma nanodrug candidate
Comparative Clinical Pathology (2016)